Cargando…

Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma

OBJECTIVE: The study evaluated the efficacy of combined epigenetic drugs of decitabine (DAC), valproic acid (VPA), and trichostatin A (TSA) on immunotherapy against glioma. METHODS: The expression and prognosis of MAGE-D4 in glioma were analyzed online, and the expression of MAGE-D4 and HLA-A2 in gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Shui-Qing, Zhang, Qing-Mei, Zeng, Xia, Liu, Chang, Nong, Wei-Xia, Xie, Huan, Li, Feng, Lin, Li-Na, Luo, Bin, Ge, Ying-Ying, Xie, Xiao-Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382192/
https://www.ncbi.nlm.nih.gov/pubmed/35992806
http://dx.doi.org/10.3389/fonc.2022.873639
_version_ 1784769237521268736
author Bi, Shui-Qing
Zhang, Qing-Mei
Zeng, Xia
Liu, Chang
Nong, Wei-Xia
Xie, Huan
Li, Feng
Lin, Li-Na
Luo, Bin
Ge, Ying-Ying
Xie, Xiao-Xun
author_facet Bi, Shui-Qing
Zhang, Qing-Mei
Zeng, Xia
Liu, Chang
Nong, Wei-Xia
Xie, Huan
Li, Feng
Lin, Li-Na
Luo, Bin
Ge, Ying-Ying
Xie, Xiao-Xun
author_sort Bi, Shui-Qing
collection PubMed
description OBJECTIVE: The study evaluated the efficacy of combined epigenetic drugs of decitabine (DAC), valproic acid (VPA), and trichostatin A (TSA) on immunotherapy against glioma. METHODS: The expression and prognosis of MAGE-D4 in glioma were analyzed online, and the expression of MAGE-D4 and HLA-A2 in glioma induced by epigenetic drugs was detected by qRT-PCR, Western blot, and flow cytometry. The methylation status of the MAGE-D4 promoter was determined by pyrosequencing. An HLA-A2 restricted MAGE-D4 peptide was predicted and synthesized. An affinity assay and a peptide/HLA complex stability assay were performed to determine the affinity between peptide and HLA. CCK8 assay, CFSE assay, ELISA and ELISPOT were performed to detect the function of MAGE-D4 peptide-specific T cells. Flow cytometry, ELISA, and cytotoxicity assays were used to detect the cytotoxicity effect of MAGE-D4 peptide-specific T cells combined with epigenetic drugs against glioma in vitro. Finally, the glioma-loaded mouse model was applied to test the inhibitory effect of specific T cells on gliomas in vivo. RESULTS: MAGE-D4 was highly expressed in glioma and correlated with poor prognosis. Glioma cells could be induced to express MAGE-D4 and HLA-A2 by epigenetic drugs. MAGE-D4-associated peptides were found that induce DCs to stimulate the highest T-cell activities of proliferation, IL-2 excretion, and IFN-γ secretion. MAGE-D4 peptide-specific T cells treated with TSA only or combining TSA and DAC had the most cytotoxicity effect, and its cytotoxicity effect on glioma cells decreased significantly after HLA blocking. In vivo experiments also confirmed that MAGE-D4-specific T cells inhibit TSA-treated glioma. CONCLUSION: MAGE-D4 is highly expressed in glioma and correlated with the prognosis of glioma. The novel MAGE-D4 peptide identified was capable of inducing MAGE-D4-specific T cells that can effectively inhibit glioma growth, and the epigenetic drug application can enhance this inhibition.
format Online
Article
Text
id pubmed-9382192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93821922022-08-18 Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma Bi, Shui-Qing Zhang, Qing-Mei Zeng, Xia Liu, Chang Nong, Wei-Xia Xie, Huan Li, Feng Lin, Li-Na Luo, Bin Ge, Ying-Ying Xie, Xiao-Xun Front Oncol Oncology OBJECTIVE: The study evaluated the efficacy of combined epigenetic drugs of decitabine (DAC), valproic acid (VPA), and trichostatin A (TSA) on immunotherapy against glioma. METHODS: The expression and prognosis of MAGE-D4 in glioma were analyzed online, and the expression of MAGE-D4 and HLA-A2 in glioma induced by epigenetic drugs was detected by qRT-PCR, Western blot, and flow cytometry. The methylation status of the MAGE-D4 promoter was determined by pyrosequencing. An HLA-A2 restricted MAGE-D4 peptide was predicted and synthesized. An affinity assay and a peptide/HLA complex stability assay were performed to determine the affinity between peptide and HLA. CCK8 assay, CFSE assay, ELISA and ELISPOT were performed to detect the function of MAGE-D4 peptide-specific T cells. Flow cytometry, ELISA, and cytotoxicity assays were used to detect the cytotoxicity effect of MAGE-D4 peptide-specific T cells combined with epigenetic drugs against glioma in vitro. Finally, the glioma-loaded mouse model was applied to test the inhibitory effect of specific T cells on gliomas in vivo. RESULTS: MAGE-D4 was highly expressed in glioma and correlated with poor prognosis. Glioma cells could be induced to express MAGE-D4 and HLA-A2 by epigenetic drugs. MAGE-D4-associated peptides were found that induce DCs to stimulate the highest T-cell activities of proliferation, IL-2 excretion, and IFN-γ secretion. MAGE-D4 peptide-specific T cells treated with TSA only or combining TSA and DAC had the most cytotoxicity effect, and its cytotoxicity effect on glioma cells decreased significantly after HLA blocking. In vivo experiments also confirmed that MAGE-D4-specific T cells inhibit TSA-treated glioma. CONCLUSION: MAGE-D4 is highly expressed in glioma and correlated with the prognosis of glioma. The novel MAGE-D4 peptide identified was capable of inducing MAGE-D4-specific T cells that can effectively inhibit glioma growth, and the epigenetic drug application can enhance this inhibition. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382192/ /pubmed/35992806 http://dx.doi.org/10.3389/fonc.2022.873639 Text en Copyright © 2022 Bi, Zhang, Zeng, Liu, Nong, Xie, Li, Lin, Luo, Ge and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bi, Shui-Qing
Zhang, Qing-Mei
Zeng, Xia
Liu, Chang
Nong, Wei-Xia
Xie, Huan
Li, Feng
Lin, Li-Na
Luo, Bin
Ge, Ying-Ying
Xie, Xiao-Xun
Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title_full Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title_fullStr Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title_full_unstemmed Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title_short Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma
title_sort combined treatment with epigenetic agents enhances anti-tumor activity of mage-d4 peptide-specific t cells by upregulating the mage-d4 expression in glioma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382192/
https://www.ncbi.nlm.nih.gov/pubmed/35992806
http://dx.doi.org/10.3389/fonc.2022.873639
work_keys_str_mv AT bishuiqing combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT zhangqingmei combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT zengxia combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT liuchang combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT nongweixia combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT xiehuan combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT lifeng combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT linlina combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT luobin combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT geyingying combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma
AT xiexiaoxun combinedtreatmentwithepigeneticagentsenhancesantitumoractivityofmaged4peptidespecifictcellsbyupregulatingthemaged4expressioninglioma